Insider Selling: Gilead Sciences, Inc. (NASDAQ:GILD) Director Sells 189 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) Director Javier Rodriguez sold 189 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $75.50, for a total transaction of $14,269.50. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Shares of Gilead Sciences stock traded down $1.56 on Thursday, reaching $74.37. The company had a trading volume of 4,051,708 shares, compared to its average volume of 11,758,681. The firm’s 50 day moving average price is $75.77 and its two-hundred day moving average price is $71.78. The firm has a market cap of $93.84 billion, a PE ratio of 19.20, a PEG ratio of 3.39 and a beta of 0.68. Gilead Sciences, Inc. has a 52-week low of $60.89 and a 52-week high of $85.97. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.92 and a current ratio of 3.04.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.11. Gilead Sciences had a net margin of 21.84% and a return on equity of 35.44%. The firm had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.44 billion. During the same period in the prior year, the firm earned $1.67 EPS. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 6.4 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Friday, June 12th will be paid a dividend of $0.68 per share. This represents a $2.72 annualized dividend and a yield of 3.66%. The ex-dividend date is Thursday, June 11th. Gilead Sciences’s payout ratio is currently 44.30%.

A number of institutional investors and hedge funds have recently made changes to their positions in GILD. Capital International Investors increased its stake in Gilead Sciences by 336.8% during the 1st quarter. Capital International Investors now owns 56,369,657 shares of the biopharmaceutical company’s stock worth $4,214,200,000 after buying an additional 43,464,551 shares during the period. Capital World Investors increased its stake in Gilead Sciences by 123.0% during the 1st quarter. Capital World Investors now owns 46,331,318 shares of the biopharmaceutical company’s stock worth $3,463,732,000 after buying an additional 25,555,467 shares during the period. Norges Bank purchased a new stake in Gilead Sciences during the 4th quarter worth approximately $859,602,000. Capital Research Global Investors increased its stake in Gilead Sciences by 12.7% during the 1st quarter. Capital Research Global Investors now owns 95,982,319 shares of the biopharmaceutical company’s stock worth $7,175,643,000 after buying an additional 10,849,434 shares during the period. Finally, Valueworks LLC increased its stake in Gilead Sciences by 7,777.5% during the 4th quarter. Valueworks LLC now owns 4,919,000 shares of the biopharmaceutical company’s stock worth $6,146,000 after buying an additional 4,856,556 shares during the period. 80.15% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms recently weighed in on GILD. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Monday, June 1st. ValuEngine lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Friday, May 1st. Wells Fargo & Co restated a “hold” rating and set a $84.00 price target on shares of Gilead Sciences in a research report on Friday, May 1st. Cantor Fitzgerald boosted their price target on shares of Gilead Sciences from $78.00 to $86.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 7th. Finally, Oppenheimer restated a “buy” rating on shares of Gilead Sciences in a research report on Monday, May 18th. Five equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and ten have given a buy rating to the company. Gilead Sciences has an average rating of “Hold” and an average target price of $79.62.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: Cost of Equity For A Business, Investors

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.